Contrary to the decade-long trend of outsourcing to CDMOs, major pharmaceutical companies are now vertically re-integrating their supply chains. Driven by supply chain vulnerabilities, they now view manufacturing not as a cost center but as a strategic advantage, creating opportunities for technology enablers rather than just capacity providers.

The first quarter of 2026 marked a 10-year high for the quantity of public biotech acquisitions, with nine deals announced. While the total dollar value of $32 billion is typical, the high frequency indicates broad-based demand from pharma and a healthy, active M&A market that can recycle capital back into the industry.

The medtech industry is uniquely squeezed by tariffs, inflation, and an inability to raise prices, crushing margins and valuations. This financial pressure has driven stock multiples to near all-time lows, signaling a major acquisition opportunity for private equity firms.

A capacity crunch in the US sterile fill market is driven by two factors: large pharmaceutical companies acquiring CDMO facilities for their own use, and a growing client demand for US-based manufacturing (reshoring). This creates a significant shortage and an opportunity for independent CDMOs with available capacity.

Years ago, MedTech M&A was driven by acquiring revenue and customer lists. Today, the priority has shifted to acquiring scarce, specialized technical capabilities and regulatory infrastructure that are difficult and time-consuming to build internally, signaling a major evolution in valuation drivers.

Increasing device complexity has outpaced the capabilities of most Original Equipment Manufacturers (OEMs). Advanced manufacturing platforms are now strategic assets, not just vendors, driving a shift in M&A focus from traditional devices to the organizations that can build them.

Private equity firms are again actively pursuing life sciences carve-outs and platform investments. Their characteristic speed and flexibility are pressuring corporate buyers, who now face increased competition and must adapt their own processes to compete effectively on deals.

The current M&A wave is unique because it includes both public and private company takeouts. This creates a robust capital recycling engine, providing quick returns to VCs (from private sales) and public specialist funds (from public takeouts). This capital is then immediately redeployed into new early and later-stage companies, sustaining the innovation ecosystem.

The current MedTech M&A market is a virtuous cycle feeding itself. Private Equity exits of mature CDMO platforms provide acquisition targets for OEMs. Simultaneously, OEM carve-outs of non-core manufacturing assets create new platform investment opportunities for PE firms.